Swiss National Bank Has $96.17 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Swiss National Bank reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% in the 4th quarter, Holdings Channel reports. The firm owned 232,600 shares of the company’s stock after selling 12,500 shares during the period. Swiss National Bank’s holdings in IDEXX Laboratories were worth $96,166,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories in the 4th quarter worth approximately $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Performance

IDXX opened at $415.30 on Friday. The stock has a market cap of $33.78 billion, a PE ratio of 38.92, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The stock’s 50 day simple moving average is $438.03 and its 200-day simple moving average is $447.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.